Description
The PD-L1 (SP142) test is an immunohistochemistry (IHC) assay used to detect the presence and level of PD-L1 protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tissue samples. It is a companion diagnostic assay, meaning it helps determine if a patient is eligible for treatment with a specific drug, in this case, atezolizumab. The SP142 assay is particularly important in triple-negative breast cancer (TNBC) and urothelial carcinoma.
Reviews
There are no reviews yet.